What is the price-to-earnings ratio of Pharnext?
The price-earnings ratio of Pharnext is currently 0.
Pharnext P/E 2024
Pharnext P/E
0
Ticker
ALPHA.PA
ISIN
FR0011191287
WKN
A2AM02
As of Sep 17, 2024, Pharnext's P/E ratio was 0, a 0% change from the -0.03 P/E ratio recorded in the previous year.
The Pharnext P/E history
Pharnext Aktienanalyse
What does Pharnext do?
Pharnext SA is a French biopharmaceutical company specializing in the development of innovative therapies for neurological diseases. The company was founded in 2007 by Professor Daniel Cohen and is headquartered in Paris. Pharnext's focus is on identifying synergistic effects of existing drugs to develop novel and effective therapies. The business model of Pharnext is based on the concept of "pleotherapy," which involves using multiple drugs simultaneously. These drug combinations are optimized to act synergistically and achieve better treatment outcomes than individual drugs alone. This allows Pharnext to achieve higher efficacy and lower toxicity. Pharnext operates in two main areas: developing therapies for neurological diseases such as Alzheimer's, Parkinson's, MND (Motoneuron Disease), Charcot-Marie-Tooth (CMT), and other rare diseases, and providing analysis and diagnostic tools for rare diseases. A significant product of Pharnext is PXT3003, a proprietary combination of three drugs for the treatment of Charcot-Marie-Tooth (CMT). PXT3003 is in Phase III clinical development and has the potential to be a groundbreaking therapy for one of the most common hereditary neuropathies worldwide. The company is also developing other products, such as PXT864 for Alzheimer's, PXT002331 for Parkinson's, and PXT002331 for MND, all of which are in clinical development. Pharnext also collaborates with other biotech and pharmaceutical companies to leverage synergies and advance the development of its therapies. For example, the company collaborates with Ipsen for the development of PXT3003 and with Galapagos for the development of drug candidates against inflammatory diseases. Overall, Pharnext aims to take a leading role in the development of therapies for neurological diseases. The company focuses on innovative approaches to maximize the potential of drug combinations and develop novel and effective therapies. Pharnext ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Pharnext's P/E Ratio
The Price to Earnings (P/E) Ratio of Pharnext is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Pharnext's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Pharnext is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Pharnext’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Pharnext stock
How has the price-earnings ratio of Pharnext changed compared to last year?
The price-to-earnings ratio of Pharnext has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Pharnext high compared to other companies?
Yes, the price-to-earnings ratio of Pharnext is high compared to other companies.
How does an increase in the price-earnings ratio of Pharnext affect the company?
An increase in the price-earnings ratio of Pharnext would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Pharnext affect the company?
A decrease in the price-earnings ratio of Pharnext would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Pharnext?
Some factors that influence the price-earnings ratio of Pharnext are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Pharnext pay?
Over the past 12 months, Pharnext paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharnext is expected to pay a dividend of 0 EUR.
What is the dividend yield of Pharnext?
The current dividend yield of Pharnext is .
When does Pharnext pay dividends?
Pharnext pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharnext?
Pharnext paid dividends every year for the past 0 years.
What is the dividend of Pharnext?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharnext located?
Pharnext is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharnext kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharnext from 9/17/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.
When did Pharnext pay the last dividend?
The last dividend was paid out on 9/17/2024.
What was the dividend of Pharnext in the year 2023?
In the year 2023, Pharnext distributed 0 EUR as dividends.
In which currency does Pharnext pay out the dividend?
The dividends of Pharnext are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharnext
Our stock analysis for Pharnext Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharnext Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
